Acumen Pharmaceuticals, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024. Acumen is a clinical-stage biopharmaceutical company developing sabirnetug (ACU193), an antibody targeting soluble amyloid-beta oligomers for Alzheimer’s disease. The company has no approved products and reported no product revenue.
Financial performance and position
- Operating expenses: $17.8 million, up 35% from $13.1 million in Q1 2023. Research and development was $12.4 million, up 43%; general and administrative expense was $5.3 million, up 20%.
- Net loss: $14.9 million versus $11.3 million a year earlier. Interest income of $4.0 million was partly offset by $1.0 million of interest expense and other expenses. Basic and diluted loss per share was $0.25 versus $0.28, with weighted-average shares increasing to 59.8 million from 41.0 million.
- Cash flow: Operating cash use was $17.9 million, compared with $10.2 million in Q1 2023. Investing cash use was $9.2 million, versus $41.9 million, reflecting lower net purchases of marketable securities. Financing provided $7.1 million, including $7.9 million of net ATM proceeds.
- Liquidity: Cash and cash equivalents were $46.9 million and marketable securities were $249.7 million at March 31, totaling $296.6 million. Working capital was $247.4 million. Management estimates current cash and marketable securities can fund operations into the first half of 2027, subject to assumptions and spending decisions.
- Debt: Long-term debt carrying value was $30.2 million. The K2 HealthVentures facility is up to $50 million; $30 million was drawn, and the remaining $20 million is subject to lender review and discretionary approval. The loan bears interest at the greater of 9.65% or prime plus 1.15%; its effective rate was 13.4% for the quarter. Principal and interest installments begin July 2026.
- Margins: Not meaningful for this pre-revenue development-stage company; the filing reports operating expenses and losses rather than product sales or gross profit.
Material changes and business developments
- R&D expense increased $3.7 million, primarily due to higher personnel costs, manufacturing and materials, contractor and consultant services, and clinical-trial-related expenses. G&A rose $0.9 million, mainly from personnel and stock-based compensation.
- Interest income increased $2.2 million year over year, reflecting higher rates and a larger investment portfolio; new loan-related interest expense partly offset the increase.
- Acumen issued 2.07 million shares through its ATM for $7.9 million net proceeds, or $3.84 per share. Shares outstanding were 60.08 million at March 31, compared with 57.91 million at December 31, 2023.
- Total assets were $301.0 million, compared with $310.1 million at year-end; stockholders’ equity was $262.0 million, down from $267.0 million. Accumulated deficit increased to $237.7 million.
Outlook, risks, and other matters
- Management expects R&D and operating losses to increase as clinical development advances. Acumen expects to need substantial additional funding to complete trials and potentially commercialize candidates; future financing may dilute shareholders or impose debt terms, and may not be available on acceptable terms.
- ALTITUDE-AD is a randomized, placebo-controlled study of sabirnetug in early Alzheimer’s disease. The company announced first-patient dosing in May 2024, after the reporting period. Planned doses are 35 mg/kg and 50 mg/kg every four weeks, with iADRS at 18 months intended as the primary outcome measure.
- Acumen intends to amend ALTITUDE-AD in 2024 from a Phase 2/3 study to a standalone Phase 2 study following EMA feedback. It also expected to initiate a Phase 1 study of a subcutaneous sabirnetug formulation in mid-2024.
- Management cited trial progress, regulatory requirements, manufacturing supply, competition, and capital-market conditions among factors that could affect funding needs and results. The company reported no material legal proceedings and no material changes to the risk factors in its 2023 Form 10-K.
- INTERCEPT-AD Phase 1 topline results previously reported by the company met primary and secondary objectives in 62 participants; the filing describes an overall ARIA-E rate of 10.4%, with dose-dependent incidence. These are prior trial results, not Q1 financial-period results.
Important facts for investors to verify
- Whether the stated runway into the first half of 2027 remains valid as trial scope, costs, and other development plans evolve.
- Progress, enrollment, protocol changes, safety, and efficacy results for ALTITUDE-AD, including the timing and design of the standalone Phase 2 study.
- Availability and terms of the undrawn $20 million loan tranche and any future financing; monitor dilution from ATM or other equity issuance.
- Clinical and regulatory prospects for sabirnetug, including the planned subcutaneous formulation trial and the implications of prior ARIA-E findings.
- Quarterly operating cash use, R&D spending, debt interest and repayment obligations, and the fair-value changes in embedded loan derivatives.